BR112013030242A2 - método de tratamento de um distúrbio autoimune em um sujeito humano - Google Patents

método de tratamento de um distúrbio autoimune em um sujeito humano

Info

Publication number
BR112013030242A2
BR112013030242A2 BR112013030242A BR112013030242A BR112013030242A2 BR 112013030242 A2 BR112013030242 A2 BR 112013030242A2 BR 112013030242 A BR112013030242 A BR 112013030242A BR 112013030242 A BR112013030242 A BR 112013030242A BR 112013030242 A2 BR112013030242 A2 BR 112013030242A2
Authority
BR
Brazil
Prior art keywords
treating
human subject
autoimmune disorder
autoimmune
disorder
Prior art date
Application number
BR112013030242A
Other languages
English (en)
Inventor
Dominique Ethgen
Gabriel Robbie
Lorin Roskos
Rajesh Narwal
Ryan Criste
Wendy White
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of BR112013030242A2 publication Critical patent/BR112013030242A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112013030242A 2011-05-25 2012-05-23 método de tratamento de um distúrbio autoimune em um sujeito humano BR112013030242A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161489949P 2011-05-25 2011-05-25
PCT/US2012/039098 WO2012162367A1 (en) 2011-05-25 2012-05-23 Methods of treating systemic lupus erythematosus, scleroderma, and myositis with an antibody against interferon-alpha

Publications (1)

Publication Number Publication Date
BR112013030242A2 true BR112013030242A2 (pt) 2016-12-06

Family

ID=47217695

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013030242A BR112013030242A2 (pt) 2011-05-25 2012-05-23 método de tratamento de um distúrbio autoimune em um sujeito humano

Country Status (9)

Country Link
EP (1) EP2714080A4 (pt)
JP (1) JP2014516970A (pt)
KR (1) KR20140043402A (pt)
CN (1) CN103732251A (pt)
BR (1) BR112013030242A2 (pt)
CA (1) CA2836926A1 (pt)
MX (1) MX2013013785A (pt)
RU (1) RU2013157177A (pt)
WO (1) WO2012162367A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9580501B2 (en) 2011-12-16 2017-02-28 Synthon Biopharmaceuticals B.V. Anti-TNF alpha monoclonal secretory IgA antibodies and methods for treating inflammatory diseases
WO2013101771A2 (en) * 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
EP3008175B1 (en) * 2013-06-15 2019-08-07 Tocagen Inc. Immunosuppressive viral like particles based on gammaretrovirus
CN103740755A (zh) * 2013-12-23 2014-04-23 中国农业大学 猪ifit1基因在抗prrs病毒中的应用
RU2580301C1 (ru) * 2015-04-21 2016-04-10 Людмила Николаевна Хон Способ лечения системной красной волчанки человека
CN107058521B (zh) * 2017-03-17 2019-12-27 中国科学院北京基因组研究所 一种检测人体免疫状态的检测系统
US20210358575A1 (en) * 2018-10-11 2021-11-18 Vivia Biotech Sl A method for determining the efficacy of treatment with a combination of drugs in a subject diagnosed with a disease and a method for classifying the utility of drug combinations in treatment of said subject
CN113692287A (zh) * 2018-10-26 2021-11-23 詹森生物科技公司 I型干扰素标记及使用方法
MA55559A (fr) * 2019-04-04 2022-02-09 Janssen Biotech Inc Procédé d'administration d'un anticorps anti-ifn-alpha/-oméga

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
NZ547157A (en) * 2003-12-10 2009-07-31 Medarex Inc Interferon Alpha Antibodies and their uses
CA2613512A1 (en) * 2005-06-23 2007-01-04 Medimmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
WO2009061818A1 (en) * 2007-11-05 2009-05-14 Medimmune, Llc Methods of treating scleroderma
CA2722622C (en) * 2008-05-07 2018-01-02 Novo Nordisk A/S Humanized antibodies against human interferon-alpha
WO2010042705A1 (en) * 2008-10-09 2010-04-15 Medimmune, Llc Antibody formulation
AR086074A1 (es) * 2011-04-26 2013-11-13 Genentech Inc Composiciones y metodo para tratar enfermedades autoinmunes

Also Published As

Publication number Publication date
CN103732251A (zh) 2014-04-16
JP2014516970A (ja) 2014-07-17
MX2013013785A (es) 2014-07-28
WO2012162367A1 (en) 2012-11-29
RU2013157177A (ru) 2015-06-27
EP2714080A1 (en) 2014-04-09
EP2714080A4 (en) 2014-11-19
CA2836926A1 (en) 2012-11-29
KR20140043402A (ko) 2014-04-09

Similar Documents

Publication Publication Date Title
BR112013030242A2 (pt) método de tratamento de um distúrbio autoimune em um sujeito humano
HK1201608A1 (en) Captcha provision method and program
GB2503623B (en) A method for predicting a result of a treatment of keratinous fibers
EP2836924A4 (en) METHOD AND DEVICE FOR INTELLECTUAL MODELING AND PREDICTION
BR112014004125A2 (pt) dispositivo e método de processamento de imagem, e, programa
BR112013023993A2 (pt) método e aparelho para fornecer interface gráfica de usuário
BR112013033633A2 (pt) método de formação de um laminado elástico
EP2755547A4 (en) SYSTEM AND METHOD FOR ASSESSING THE NETWORK SKIN FUNCTION
BR112014001973A2 (pt) composto e método de tratamento do câncer em um sujeito
EP2752776A4 (en) METHOD AND DEVICE FOR DETECTING NOMINATED UNITS
BR112013022931A2 (pt) dispositivo receptor, método de recepção, e, programa
BR112014008913A2 (pt) dispositivo de controle de ação, método de controle de ação de um dispositivo de controle de ção, programa, e, dispositivo de formação de imagem
BR112014011529A2 (pt) dispositivo de tratamento de água e método de tratamento de água
BR112013022539A2 (pt) dispositivo receptor, método de recepção, e, programa
BR112013029204A2 (pt) dispositivo e método de processamento de imagem, e, programa
GB201315890D0 (en) Applicability determination program, failure prediction device and applicability determination method
BR112013022820A2 (pt) método de tratamento
EP2733605A4 (en) METHOD AND MANAGEMENT DEVICE FOR WEB PAGE APPLICATION PROGRAM
EP2915626A4 (en) DEVICE AND METHOD FOR GENERATING A PROCESSING PROGRAM
BR112014002132A2 (pt) dispositivo e método de processamento de imagem, e, programa
EP2766716A4 (en) METHOD AND SYSTEMS FOR IMPLEMENTING BIOMETRIC FUNCTIONS
BR112013023142A2 (pt) método de tratamento de cabelos
EP2725440A4 (en) PREDICTION DEVICE, PREDICTION METHOD, AND PREDICTION PROGRAM
BR112014010507A2 (pt) aparelho de formaçãode imagem, método para controlar o mesmo, e programa
BR112014010688A2 (pt) dispositivo, método e programa de processamento de imagem

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]